Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

PloS one - 1 Jan 2017

Pascual Tomas, Apellániz-Ruiz María, Pernaut Cristina, Cueto-Felgueroso Cecilia, Villalba Pablo, Álvarez Carlos, Manso Luis, Inglada-Pérez Lucia, Robledo Mercedes, Rodríguez-Antona Cristina, Ciruelos Eva

Abstract excerpt

PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability in toxicity and response to exemestane-everolimus treatment. The objective of this study was to perform an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Everolimus

Share to Pharmacogenetics

Share to Prognosis

Share to Survival Rate

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 28727815
DOI: 10.1371/journal.pone.0180192
PMCID: PMC5519037

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.PMID 28727815Read ↗

Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients.Semantic proximity Read ↗

Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.Semantic proximity Read ↗

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Semantic proximity Read ↗

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.Semantic proximity Read ↗

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trialSemantic proximity Read ↗

Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.Semantic proximity Read ↗

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER StudySemantic proximity Read ↗

The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.